Table 2.

Summary of adverse events

AEs, n (%)	Ecnoglutide			Placebo N = 36
	0.4 mg  N = 37	0.8 mg  N = 36	1.2 mg  N = 36
All AE	29 (78.4)	28 (77.8)	26 (72.2)	22 (61.1)
All TRAE	18 (48.6)	16 (44.4)	16 (44.4)	6 (16.7)
TEAE ≥Grade 3	2 (5.4)	0	2 (5.6)	3 (8.3)
TRAE ≥Grade 3	0	0	0	0
All AESI	14 (37.8)	13 (36.1)	17 (47.2)	6 (16.7)
Treatment-related AESI	14 (37.8)	12 (33.3)	15 (41.7)	2 (5.6)
TEAE leading to drug discontinuation	0	0	1 (2.8)	0
TRAE leading to drug discontinuation	0	0	1 (2.8)	0
All SAE	0	0	1 (2.8)	0
Treatment-related SAE	0	0	0	0
TEAE leading to study withdrawal	0	0	2 (5.6)	0
TRAE leading to study withdrawal	0	0	1 (2.8)	0
TEAE leading to death	0	0	0	0
TRAE leading to death	0	0	0	0

AE adverse event, TRAE treatment-related AE, TEAE treatment-emergent AE, AESI adverse events of special interest, SAE serious adverse event.